Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cyxone. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cyxone's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Cyxone is high growth as no earnings estimate data is available.
Cyxone's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cyxone's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Kjell G. Stenberg, Ph.D., serves as the Chief Executive Officer of Cyxone AB (publ). Dr. Stenberg serves as the Chief Marketing Officer of Aptahem AB (publ) and serves as its Chairman. Dr. Stenberg serves as the Chief Executive Officer of Accequa AB and Celus Parmaceuticals Ltd, USA. He is the owner of Biomedical Development Europe. He served as the Chief Operating Officer of Medwell Capital Corp. from November 17, 2005 to October 5, 2010. He served as Partner of Medwell Capital Corp. Dr. Stenberg has 25 years experience from management positions in R&D. He was the founder of Combio A/S in 2001 and served as its Chief Executive Officer. He served as Chief Scientific Officer positions in CePeP AB and Orexo AB. He served as Chief Operating Officer of BioMS Medical Corp. He served as Senior Researcher, Director and Manager of Astra/AstraZeneca from 1975 to 2000, where he was involved in bringing various drugs to market either as Director of Research or Director of Development. From 1975 to 2000, Dr. Stenberg held senior research and management positions at Astra and AstraZeneca, where his responsibilities included directing research in multiple sclerosis, management of international development teams and being the Director of External Alliances for the development of products related to the Central Nervous System (which included MS). Dr. Stenberg has also been involved with three biotech companies at the level of Founder, Chief Executive Officer and Chief Scientific Officer. He served as a Director of PCI Biotech AS since 2013. He serves as the Chairman of The Board at Galecto Biotech AB. He served as a Director of Cyxone AB (publ). He serves as a Director of Novation Pharmaceuticals, Inc., Galecto AB and Aptahem AB (publ). He served as a Director of PCI Biotech Holding ASA since May 6, 2013 until 2015. He served as a Director of Medwell Capital Corp. from 2002 to October 5, 2010. He has published extensively in the field of oncology and cell toxicology. He served as Director of Orexo AB. Dr. Stenberg holds a Ph.D. in Medical Science from the Karolinska Institute, Sweden.
Insufficient data for Kjell to compare compensation growth.
Insufficient data for Kjell to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Cyxone AB (publ), a clinical biotech company, develops cyclotide drugs for autoimmune and other diseases. Its lead candidate is Rabeximod, which is in Phase II clinical trial for the treatment of patients with rheumatoid arthritis. The company also develops T20K that is in pre-clinical trial for the treatment of pro-inflammatory cytokines, such as IL2 and reduces clinical symptoms in an animal model for multiple sclerosis after oral administration. The company was founded in 2015 and is based in Malmo, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.